Related references
Note: Only part of the references are listed.Lumasiran: First Approval
Lesley J. Scott et al.
DRUGS (2021)
Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient
Caroline Kempf et al.
PEDIATRIC NEPHROLOGY (2020)
Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning
Marine Le Dudal et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
Chengjung Lai et al.
MOLECULAR THERAPY (2018)
Characteristics and Outcomes of Children with Primary Oxalosis Requiring Renal Replacement Therapy
Jerome Harambat et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Primary hyperoxaluria Type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort
S. M. van der Hoeven et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
Pierre Cochat et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1
F. Illies et al.
KIDNEY INTERNATIONAL (2006)
Long-term analysis of combined liver and kidney transplantation at a single center
Richard Ruiz et al.
ARCHIVES OF SURGERY (2006)
Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele
CG Monico et al.
KIDNEY INTERNATIONAL (2005)
Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome
CS van Woerden et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Share Paper
